Company Announcement
- Genmab A/S to hold Annual General Meeting on March 17, 2016
Copenhagen, Denmark; February 23, 2016 – Genmab A/S (Nasdaq Copenhagen: GEN) summons the Annual General Meeting on Thursday, March 17, 2016 at 2:00 PM CET at the Tivoli Hotel & Congress Center, Arni Magnussons Gade 2-4, DK-1577 Copenhagen V, Denmark.
Agenda:
1. Report by the Board of Directors on the Company’s activities during the past year.
2. Presentation and adoption of the audited Annual Report 2015 and resolution to discharge the Board of Directors and the Executive Management from liability.
3. Resolution on the distribution of profits as recorded in the adopted Annual Report.
4. Election of members of the Board of Directors.
5. Election of auditor.
6. Proposals from the Board of Directors:
(a) Amendment of the general guidelines for incentive-based remuneration of the Board of Directors and the Executive Management.
(b) Authorization of the Board of Directors to allow the Company to repurchase own shares.
(c) Approval of remuneration to the Board of Directors for 2016.
(d) Amendment of Article 6 of the Company’s Articles of Association changing the Company’s shares from bearer shares to shares issued in the name of the holder.
(e) Amendment of Article 8 of the Company’s Articles of Association to the effect that the requirement for the General Meeting to be convened through the IT system of the Danish Business Authority is deleted.
(f) Amendment of Article 4A of the Company’s Articles of Association on authorization to issue shares.
(g) Amendment of Article 5 of the Company's Articles of Association on authorization to issue warrants.
(h) Amendment of Article 5A of the Company's Articles of Association on authorization to raise loans against bonds or other financial instruments.
(i) Amendment of Article 15 of the Company’s Articles of Association on the signatory rule of the Company.
7. Authorization of the chairman of the General Meeting.
8. Any other business.
Complete Proposals
Re item 1 on the agenda:
It is proposed to take note of the report of the Board of Directors.
Re item 2 on the agenda:
It is proposed to adopt the audited Annual Report and to grant discharge to the Board of Directors and the Executive Management.
Re item 3 on the agenda:
It is proposed that the profit of DKK 838 million for the accounting year 2015 be carried forward by transfer to the accumulated deficit.
Re item 4 on the agenda:
Pursuant to Article 12 of the Company’s Articles of Association, the members of the Board of Directors are elected for periods of one year. The election period for Mats Pettersson, Dr. Anders Gersel Pedersen, Pernille Erenbjerg, Dr. Burton G. Malkiel and Dr. Paolo Paoletti expires at this General Meeting. The Board of Directors proposes to re-elect Mats Pettersson, Dr. Anders Gersel Pedersen, Pernille Erenbjerg, Dr. Burton G. Malkiel and Dr. Paolo Paoletti for a one-year period.
The Genmab group’s employees will elect three employee representatives on March 11, 2016 for the Company's Board of Directors in accordance with Article 12 of the Articles of Association and the provisions of the Danish Companies Act.
About Mats Pettersson, B.Sc.
Swedish, 70, Male
Board Chairman (Independent, elected by the General Meeting); Chairman of the Nominating and Corporate Governance Committee and member of the Audit Committee and the Compensation Committee.
First elected 2013, current term expires 2016.
Special Competences
Extensive experience from international research-based biotech and pharmaceutical companies. Founder and CEO of SOBI AB. Responsible for several transforming business development deals and member of various executive management committees at Pharmacia.
Current Board Positions
Chairman: Moberg Pharma AB.
About Anders Gersel Pedersen, M.D., Ph.D.
Danish, 64, Male
Deputy Chairman (Non-independent, elected by the General Meeting); Chairman of the Compensation Committee and member of the Nominating and Corporate Governance Committee.
First elected 2003, current term expires 2016.
Special Competences
Business and management experience in the pharmaceutical industry, including expertise in clinical research, development, regulatory affairs and product life cycle management.
Current Position, Including Managerial Positions
Executive Vice President, Research & Development at H. Lundbeck A/S.
Current Board Positions
Member: ALK-Abelló A/S.
Deputy Chairman: Bavarian Nordic A/S.
About Pernille Erenbjerg
Danish, 48, Female
Board member (Independent, elected by the General Meeting);
Member of the Audit Committee and the Nominating and Corporate Governance Committee.
First elected 2015, current term expires 2016.
Special Competences
Senior executive management and broad business experience from the telecoms industry. Comprehensive all round background within finance including extensive exposure to stock markets, equity and debt investors. Certified Public Accountant background. Responsible for major transformation processes in complex organizations including M&A.
Current Position, Including Managerial Positions
Group CEO and President of TDC A/S.
Current Board Positions
Member: DFDS A/S.
Audit Committee Chairman: DFDS A/S.
Member of the Fiscal Policy Committee of the Confederation of Danish Industry.
Member of the Business Policy Committee of the Confederation of Danish Industry.
About Burton G. Malkiel, Ph.D.
American, 83*, Male
Board member (Independent, elected by the General Meeting); Chairman of the Audit Committee.
First elected 2007, current term expires 2016.
Special Competences
Extensive expertise in economics and finance, particularly relating to securities valuation and corporate finance; significant board and audit committee experience.
Current Position, Including Managerial Positions
Chemical Bank Chairman’s Professor Emeritus of Economics at Princeton University and Chief Investment Officer at Wealthfront, Inc.
Current Board Positions
Member: Vanguard Group Ltd., Theravance Biopharma, Inc., American Philosophical Society and Maldeb Foundation.
Audit Committee Chairman: Theravance Biopharma, Inc.
Investment Committee Member: American Philosophical Society and Maldeb Foundation.
About Paolo Paoletti, M.D.
Italian (USA citizenship), 65, Male
Board member (Independent, elected by the General Meeting); Member of the Compensation Committee.
First elected 2015, current term expires 2016.
Special Competences
Extensive experience in research, development and commercialization in the pharmaceutical industry. Successfully conducted submissions and approvals of new cancer drugs and new indications in the USA and in Europe. Responsible for seven new medicines for cancer patients during his 10 years at GlaxoSmithKline and one new cancer medicine during his time at Eli Lilly. Last position in GlaxoSmithKline: President of Oncology Business Unit.
Current Position, Including Managerial Positions
CEO at Kesios Therapeutics Limited.
Current Board Positions
Chairman: PsiOxus Therapeutics Limited.
Member: Kesios Therapeutics Limited, FORMA Therapeutics, Inc. and NuCana BioMed Limited.
*Dr. Burton G. Malkiel is 83 years old and has, thus, exceeded the age limit stated in Article 12 of the Articles of Association. Re-election will therefore require that the proposal is adopted by the same majority as required for the adoption of a resolution to alter the Articles of Association.
Re item 5 on the agenda:
The Board of Directors proposes re-election of PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab as the Company’s elected auditor.
Re item 6 (a) on the agenda:
The Board of Directors proposes that the Company's general guidelines for incentive-based remuneration for the Board of Directors and the Executive Management are amended so that the maximum ordinary bonus that a member of the Executive Management may earn per calendar year is increased from DKK 6 million to DKK 10 million and so that the maximum extraordinary bonus is increased from DKK 1 million to DKK 1.5 million. The motivation behind the proposed amendment is to ensure that a competitive compensation package can be offered to current and future members of the Executive Management.
It is further proposed that the proportional value (at the time of grant) of the restricted stock units that a member of the Board of Directors may be granted on an annual basis is lowered. As a result hereof, the maximum value (in DKK) of restricted stock units that may be granted to members of the Board of Directors on an annual basis will remain unchanged notwithstanding the increase in the basic fee for members of the Board of Directors proposed under item 6(c).
Furthermore, the general guidelines have been subject to a general update and minor editorial changes.
Re item 6 (b) on the agenda:
The Board of Directors proposes that the Annual General Meeting authorizes the Board of Directors to allow the Company to repurchase up to a total nominal amount of DKK 500,000 own shares, corresponding to 0.84% of the share capital, in accordance with applicable law. The purchase price for the relevant shares may not deviate by more than 10% from the price quoted on Nasdaq Copenhagen A/S at the time of the acquisition. This authorization will replace the authorization to repurchase up to a total nominal amount of DKK 250,000 own shares granted by the General Meeting on April 9, 2014 and shall remain in force for a period ending on March 17, 2021.
The proposal is intended to ensure that the Company can cover its obligations under the Company’s restricted stock unit program.
Re item 6 (c) on the agenda:
The Board of Directors proposes that the basic fee for members of the Board of Directors is increased from DKK 300,000 to DKK 375,000, and that the deputy chairman receives two times the increased basic fee and that the chairman receives three times the increased basic fee. In addition to these fees, it is proposed that the members of the board committees receive a supplemental fee of up to DKK 75,000, that a committee chairman receives up to DKK 150,000, and that the committee members receive a fee of DKK 9,000 per committee meeting. Members of the Board of Directors will furthermore receive share-based instruments in the form of restricted stock units within the scope described and adopted in the Company’s general guidelines for incentive-based remuneration for the Board of Directors and the Executive Management. Apart from the increase in the basic fee for members of the Board of Directors, the remuneration for 2016 is identical to the Board of Directors' remuneration for 2015.
Re item 6 (d) on the agenda:
The Board of Directors proposes an amendment of Article 6(1), first sentence of the Company’s Articles of Association to change the Company’s shares from bearer shares to shares issued in the name of the holder. The background for this proposal is partly that due to recent amendments to the Danish Companies Act it is no longer possible as from July 1, 2015 to issue new bearer shares, partly that the transitional rule related to the amendment to the Act regarding existing authorities to increase companies’ capital is only effective until July 1, 2016.
The proposal means that Article 6(1), first sentence, will read as follows:
“The shares are issued in the name of the holder and are entered in the name of their holders in the Company’s Register of Shareholders.”
Re item 6 (e) on the agenda:
The Board of Directors proposes to delete the reference in Article 8(4), first sentence, in the Company's Articles of Association regarding the summoning of General Meetings through the IT System of the Danish Business Authority as summoning through the Business Authorities' IT System is not a requirement when the Company's shares are issued in the name of the holder. Article 8(4), first sentence, is therefore proposed amended as follows:
“The Board of Directors shall call the General Meeting with no less than three (3) weeks' notice and not more than five (5) weeks' notice by notification to Nasdaq Copenhagen and by posting on the Company's website (www.genmab.com).”
Re item 6 (f) on the agenda:
The Board of Directors proposes an amendment of Article 4A(1), fourth sentence, and Article 4A(2), third sentence of the Company’s Articles of Association as a result of the proposal under item 6(d) above (changing the Company's shares from bearer shares to shares issued in name of the holder) so that the Board of Directors be authorised to issue shares in the name of the holder instead of bearer shares.
The proposal means that Article 4A(1), fourth sentence and Article 4A(2), third sentence will read as follows:
“No transferability restrictions or redemption obligations shall apply to the new shares. The shares shall be negotiable instruments, issued in the name of the holder and registered in the name of the holder in the Company’s Register of Shareholders.”
Re item 6 (g) on the agenda:
The Board of Directors proposes that Article 5 of the Company's Articles of Association be amended so that the Board of Directors is authorised to issue an additional 500,000 warrants entitling the holder to subscribe for the Company's shares up to a nominal value of DKK 500,000.
It is further proposed to amend Article 5 to specify that the Board of Directors’ authorizations entitle the Board of Directors to issue warrants to, amongst others, employees and consultants employed in the Company's directly and indirectly owned subsidiaries. This change is a result of Genmab B.V. having become a wholly-owned subsidiary of Genmab Holding B.V.
The proposal means that Article 5 of the Articles of Association will read as follows:
Ӥ 5
By decision of the General Meeting on April 25, 2012 the Board of Directors is authorized to issue on one or more occasions warrants to subscribe the Company’s shares up to a nominal value of DKK 250,000 and to make the related capital increases in cash up to a nominal value of DKK 250,000. The Board of Directors has issued 250,000 warrants and reissued 41,625 warrants under this authorization. This authorization shall remain in force for a period ending on April 25, 2017.
Further, by decision of the General Meeting on April 17, 2013 the Board of Directors is authorized to issue on one or more occasions additional warrants to subscribe the Company’s shares up to a nominal value of DKK 600,000 and to make the related capital increases in cash up to a nominal value of DKK 600,000. The Board of Directors has issued 600,000 warrants and reissued 10,250 warrants under this authorization. This authorization shall remain in force for a period ending on April 17, 2018.
Moreover, by decision of the General Meeting on April 9, 2014 the Board of Directors is authorized to issue on one or more occasions additional warrants to subscribe the Company’s shares up to a nominal value of DKK 500,000 and to make the related capital increases in cash up to a nominal value of DKK 500,000. The Board of Directors has issued 261,900 warrants and reissued 2,750 warrants under this authorization. This authorization shall remain in force for a period ending on April 9, 2019.
Moreover, by decision of the General Meeting on March 17, 2016 the Board of Directors is authorized to issue on one or more occasions additional warrants to subscribe the Company’s shares up to a nominal value of DKK 500,000 and to make the related capital increases in cash up to a nominal value of DKK 500,000. This authorization shall remain in force for a period ending on March 17, 2021.
The authorizations entitle the Board of Directors to issue warrants to members of the Company’s Board of Directors, the Company’s employees and consultants as well as employees and consultants of the Company’s directly and indirectly owned subsidiaries. Subject to the rules in force at any time, the Board of Directors may reuse or reissue lapsed non-exercised warrants, if any, provided that the reuse or reissue occurs under the same terms and within the time limitations set out in this authorization. Reuse is to be construed as the Board of Directors' entitlement to let another party enter into an existing agreement on warrants. Reissue is to be construed as the Board of Directors' option to reissue new warrants under the same authorization, if previously issued warrants have lapsed. The existing shareholders of the Company shall not have a right of pre-emption in connection with the issue of warrants based on these authorizations. One warrant shall give the right to subscribe one share with a nominal value of DKK 1 at a subscription price per share determined by the Board of Directors which, however, shall be no less than the market price per share of the Company’s shares at the time of issue.
The exercise period for the issued warrants shall be determined by the Board of Directors.
The Board of Directors is authorized to set out more detailed terms for the warrants that are to be issued based on these authorizations.
The existing shareholders of the Company shall not have a right of pre-emption in connection with issue of shares on the basis of warrants. The shares that are issued through the exercise of warrants shall have the same rights as existing shares cf. these Articles of Association.
The Board of Directors has exercised the above authorizations as stipulated in schedule A which is an integral part of these articles.”
Re item 6 (h) on the agenda:
The Board of Directors propose to amend Article 5A of the Articles of Association so that the Board of Directors’ authority to raise convertible loans is increased from a maximum amount of DKK 1.5 billion to a maximum amount of DKK 3 billion and so that the maximum number of new shares that may be issued under the authorization is lowered from 12,500,000 shares to 4,000,000 shares. The Board of Directors further propose that the authorization is extended until March 17, 2021.
It is also proposed to amend the Board of Directors’ authority in Article 5A as a result of the proposal under item 6(d) above (changing the Company's shares from bearer shares to shares issued in name of the holder) so that the Board of Directors be authorised to issue shares in the name of the holder instead of bearer shares.
The proposal means that Article 5A of the Articles of Association will read as follows:
Ҥ 5A
The Board of Directors shall be authorized, until March 17, 2021, by one or more issues to raise loans against bonds or other financial instruments up to a maximum amount of DKK 3 billion with a right for the lender to convert his claim to a maximum of nominally DKK 4,000,000 equivalent to 4,000,000 new shares (convertible loans). Convertible loans may be raised in DKK or the equivalent in foreign currency (including US dollar (USD) or euro (EUR)) computed at the rates of exchange ruling at the day of loan. The Board of Directors is also authorized to effect the consequential increase of the capital. Convertible loans may be raised against payment in cash or in other ways. The subscription of shares shall be without pre-emption rights for the shareholders and the convertible loans shall be offered at a subscription price and conversion price that in the aggregate at least corresponds to the market price of the shares at the time of the decision of the Board of Directors. The time limit for conversion may be fixed for a longer period than five (5) years after the raising of the convertible loan. The terms for raising of convertible loans as well as time and terms for the capital increase shall be decided by the Board of Directors in accordance with section 169 of the Companies Act. If the Board of Directors exercises the authorization new shares shall be issued in the name of the holder and carry dividend as of a date to be fixed by the Board of Directors. No restrictions shall apply as to the pre-emption right of the new shares, and shall rank pari passu with existing shares with respect to rights, redeemability and negotiability. The Board of Directors is authorized to amend the Articles of Association as necessary in connection with the capital increases being effected.
The Board of Directors shall be authorized, until March 17, 2021, by one or more issues to raise loans against bonds or other financial instruments up to a maximum amount of DKK 3 billion with a right for the lender to convert his claim to a maximum of nominally DKK 4,000,000 equivalent to 4,000,000 new shares (convertible loans). Convertible loans may be raised in DKK or the equivalent in foreign currency (including US dollar (USD) or euro (EUR)) computed at the rates of exchange ruling at the day of loan. The Board of Directors is also authorized to effect the consequential increase of the capital. Convertible loans may be raised against payment in cash or in other ways. The subscription of shares shall be with pre-emption rights for the shareholders and the convertible loans shall be offered at a subscription price and conversion price that in the aggregate at least corresponds to the market price of the shares at the time of the decision of the Board of Directors. The time limit for conversion may be fixed for a longer period than five (5) years after the raising of the convertible loan. The terms for raising of convertible loans as well as time and terms for the capital increase shall be decided by the Board of Directors in accordance with section 169 of the Companies Act. If the Board of Directors exercises the authorization new shares shall be issued in the name of the holder and carry dividend as of a date to be fixed by the Board of Directors. No restrictions shall apply as to the pre-emption right of the new shares, and shall rank pari passu with existing shares with respect to rights, redeemability and negotiability. The Board of Directors is authorized to amend the Articles of Association as necessary in connection with the capital increases being effected.
In connection with the exercise of these authorizations, the Board of Directors may, however, not raise loans against bonds or other financial instruments up to more than a total of DKK 3 billion and increase the nominal registered share capital by more than a total of DKK 4,000,000, equivalent to 4,000,000 new shares.”
Re item 6 (i) on the agenda:
The Board of Directors proposes that the Company's signing authority in Article 15 of the Articles of Association be clarified in the Danish version of the Articles of Association which does not result in any amendment of the English translation of Article 15. Thus, the English translation of Article 15 will still read as follows:
Ҥ 15
The Company shall be bound by the joint signature of a member of the Board of Directors and a member of the Management or by two members of the Board of Directors.”
Re item 7 on the agenda:
The Board of Directors proposes that the chairman of the General Meeting is authorized to register the resolutions passed by the General Meeting with the Danish Business Authority and to make such amendments and additions thereto or therein, including the Articles of Association of the Company, as the Danish Business Authority may require for registration.
Re-election of Dr. Burton G. Malkiel under item 4 of the agenda and adoption of the proposals under item 6 (d) and 6 (i) of the agenda to amend the Articles of Association are required to be adopted by an affirmative vote of not less than 2/3 of the votes cast as well as of the voting share capital represented at the General Meeting.
The Company's share capital amounts to DKK 59,531,263 divided into shares of DKK 1 each or any multiple hereof. Each share amount of DKK 1 shall entitle the shareholder to one vote.
__________
Pursuant to Section 99 of the Danish Companies Act, the following documents will be published on the Company’s website (www.genmab.com) no later than February 24, 2016: (1) the notice of the Annual General Meeting, (2) information on the total number of shares and votes issued by the Company on the date of the notice, (3) the agenda, (4) the complete proposals to be presented at the Annual General Meeting, (5) the Annual Report for 2015 and (6) forms needed to register for the Annual General Meeting and possible proxy voting and post voting.
Registration Date: A shareholder’s right to participate in and vote at the Annual General Meeting is determined in proportion to the number of shares the shareholders owns on the registration date Thursday March 10, 2016.
Admission card: Admission cards may be requested no later than Friday March 11, 2016 by:
- Visiting the Company’s website www.genmab.com or VP Investor Services A/S’ website www.uk.vp.dk/agm no later than 11:59 PM CET to register electronically; or
- Returning the registration form – duly completed and signed – to VP Investor Services A/S, Weidekampsgade 14, DK-2300 Copenhagen S, Denmark by post or by fax to +45 43 58 88 67 no later than 11:59 PM CET; or
- Contacting Genmab A/S, Investor Relations, Bredgade 34E, DK-1260 Copenhagen K, Denmark either in person or in writing no later than 10:00 AM CET; or
- Contacting VP Investor Services A/S telephonically at +45 43 58 88 66 no later than 10:00 AM CET.
Proxy vote: Shareholders who do not expect to be able to participate in the General Meeting may:
- Assign a proxy to a person appointed by the shareholder. Proxies shall submit a request for an admission card as described above; or
- Assign a proxy to the Board of Directors. In this case your votes will be cast in accordance with the recommendations of the Board of Directors; or
- Assign a proxy to the Board of Directors by indicating how you wish your votes to be cast
Go to the Company’s website www.genmab.com or www.uk.vp.dk/agm to assign a proxy to the Board of Directors to vote in accordance with its recommendations, or assign a proxy indicating how you wish your votes to be cast by checking the boxes on the electronic proxy form. This must be done by 11:59 PM CET on Friday March 11, 2016. You may complete and sign the proxy form and return it by post to VP Investor Services A/S, Weidekampsgade 14, DK-2300 Copenhagen S, Denmark, or scan it and return it by e-mail to vpinvestor@vp.dk or by fax to +45 43 58 88 67 so that it is received by VP Investor Services A/S by 11:59 PM CET on Friday March 11, 2016.
Postal vote: Shareholders who do not expect to be able to participate in the General Meeting may also vote by post:
Go to the Company’s website www.genmab.com or www.uk.vp.dk/agm to vote by post. This must be done by 10:00 AM CET on Wednesday March 16, 2016. You may complete and sign the postal voting form and return it by post to VP Investor Services A/S, Weidekampsgade 14, DK-2300 Copenhagen S, Denmark, or scan it and return it by e-mail to vpinvestor@vp.dk or by fax to +45 43 58 88 67 so that it is received by VP Investor Services A/S by 10:00 AM CET on Wednesday March 16, 2016.
Please note that you may either assign a proxy or vote by post, but not both.
Any shareholder, to whom admission card already has been issued, but who is prevented from attending the Annual General Meeting is kindly asked to notify the Company - preferably before Friday March 11, 2016.
Right to ask questions: Prior to the General Meeting, the shareholders may ask the Company’s management in writing about matters of importance to the evaluation of the Annual Report 2015, the Company’s position or any of the other matters which are to be transacted at the General Meeting, or the Company’s relation to other companies in the Genmab Group. Shareholders’ questions must be sent by letter to Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications or by e-mail to r.gravesen@genmab.com. The question may be answered in writing by e.g. making the answer available on the Company’s website (www.genmab.com). The question may be neglected if the shareholder asking the question is not represented at the General Meeting. At the General Meeting, the shareholders may also ask the Company’s management about the above matters and may ask questions regarding the Annual Report 2015 to the auditor appointed by the General Meeting.
About Genmab
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and DARZALEX™ (daratumumab) for the treatment of heavily pretreated or double refractory multiple myeloma. Daratumumab is in clinical development for additional multiple myeloma indications and for non-Hodgkin’s lymphoma. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com
This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.
Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody® and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX™ is a trademark of Janssen Biotech, Inc.
Company Announcement no. 04
CVR no. 2102 3884
Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark
